Sierra Oncology, a biopharmaceutical company focused on rare cancers, has announced positive results from its pivotal Phase 3 MOMENTUM study evaluating momelotinib (MMB) in myelofibrosis patients.
The trial met all primary and key secondary endpoints, demonstrating statistically significant and clinically important efficacy. The topline data showed that momelotinib achieved a >50% reduction in Total Symptom Score (TSS), increased transfusion independence rate, and improved splenic response rate compared to the control group.
The adverse events were manageable, and the full data set will be presented at an upcoming medical meeting. Momelotinib is an orally bioavailable JAK1, JAK2, and ACVR1/ALK2 inhibitor that has shown positive results for symptoms, splenic response, and anemia in myelofibrosis patients.
The findings suggest momelotinib may provide an effective treatment option for this difficult-to-treat patient population. Sierra Oncology aims to bring momelotinib to patients as quickly as possible.